Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
D000284:Administration, Oral; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002214:Capsules; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea; D010300:Parkinson Disease / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors; D014839:Vomiting
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002214:Capsules; D004338:Drug Combinations; D006834:Hydrazines; D004295:Dihydroxyphenylalanine